- Source: XF-73
XF-73 (Exeporfinium chloride) is an experimental drug candidate. It is an anti-microbial that works via weakening bacteria cell walls. It is a potential treatment for methicillin-resistant Staphylococcus aureus (MRSA) and possibly Clostridioides difficile. It is being developed by Destiny Pharma Ltd.
Structurally, it is a dicationic porphyrin.
It has completed a phase I clinical trial for nasal decolonisation of MRSA—being tested against 5 bacterial strains. It seems unlikely to cause MRSA to develop resistance to it.
In 2014, a phase 1 clinical trial for nasal administration was run.
As of June 2022, another phase 1 clinical trial (for nasal administration) completed recruiting in 2016 but no results have been posted.
References
Kata Kunci Pencarian:
- Mikoyan-Gurevich MiG-25
- McDonnell F-101 Voodoo
- SMA Negeri 14 Jakarta
- F-102 Delta Dagger
- Bulgaria pada Olimpiade Musim Panas 2024
- Swiss pada Olimpiade Musim Panas 2020
- 2008 AX28
- 2011 HQ
- 2002 RD27
- 2008 JS26
- XF-73
- Hughes XF-11
- Jaguar XF (X250)
- Curtiss-Wright XF-87 Blackhawk
- North American XF-108 Rapier
- Academic grading in the United States
- Ford Falcon (XF)
- Fujinon XF 27mm F2.8
- Hughes D-2
- Northrop F-15 Reporter
